secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001728117-25-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025
-----------------------------------------------------------------------

- Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.
- Full-year 2024 net loss $56.5M ($0.25/share) vs $179.8M ($1.18) in 2023.
- R&D expenses $138.5M in 2024 vs $135.3M in 2023; G&A $36.1M vs $38.5M.
- PROSERA Phase 3 in PAH on track for topline data readout in Q4 2025.
- PH-ILD registrational Phase 3 to commence H2 2025; seralutinib got Japan orphan PAH designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/0001728117-25-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313.htm
  HTML page:      https://secwatch.observer/filing/0001728117-25-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer